{
  "name" : "dacemirror.sci-hub.se_journal-article_d72f61fbcefb4c649c1579fbc932e78c_dong2019.pdf",
  "metadata" : {
    "source" : "CRF",
    "title" : "Carrier-Free Nano-Integrated Strategy for Synergetic Cancer Anti- angiogenic Therapy and Phototherapy",
    "authors" : [ "Zheng Wei", "Pingping Liang", "Junqi Xie", "Chuanhui Song", "Chuanchao Tang", "Yufeng Wang", "Xiteng Yin", "Yu Cai", "Wei Han", "Xiaochen Dong" ],
    "emails" : [ "iamycai@163.com.", "doctorhanwei@hotmail.com.", "iamxcdong@njtech.edu.cn" ],
    "sections" : [ {
      "heading" : null,
      "text" : "This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.\nAccepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.\nYou can find more information about Accepted Manuscripts in the author guidelines.\nPlease note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal’s standard Terms & Conditions and the ethical guidelines, outlined in our author and reviewer resource centre, still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.\nAccepted Manuscript\nrsc.li/chemical-science\nwww.rsc.org/chemicalscience\nChemical Science\nISSN 2041-6539\nVolume 7 Number 1 January 2016 Pages 1–812\nEDGE ARTICLE Francesco Ricci et al. Electronic control of DNA-based nanoswitches and nanodevices\nChemical Science\nView Article Online View Journal\nThis article can be cited before page numbers have been issued, to do this please use: X. Dong, Z. Wei, P.\nLiang, J. Xie, C. Song, C. Tang, Y. Wang, X. Yin, Y. Cai and W. Han, Chem. Sci., 2019, DOI:\n10.1039/C8SC04123G."
    }, {
      "heading" : "Chemical Science",
      "text" : "EDGE ARTICLE\nThis journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 1\nPlease do not adjust margins\nPlease do not adjust margins\na. Central Laboratory of Stomatology, Nanjing Stomatological Hospital, Medical School of Nanjing University, 30 Zhongyang Road, 210008, Nanjing, China. E-mail: iamycai@163.com. b. Department of Oral and Maxillofacial Surgery, Nanjing Stomatological Hospital, Medical School of Nanjing University, 30 Zhongyang Road, 210008, Nanjing, China. E-mail: doctorhanwei@hotmail.com. c. Key Laboratory of Flexible Electronics (KLOFE) & Institute of Advanced Materials (IAM), Nanjing Tech University (NanjingTech), 30 South Puzhu Road, 211800, Nanjing, China. E-mail: iamxcdong@njtech.edu.cn . ‡These authors contributed equally\nReceived 00th January 20xx, Accepted 00th January 20xx\nDOI: 10.1039/x0xx00000x\nwww.rsc.org/\nCarrier-Free Nano-Integrated Strategy for Synergetic Cancer Antiangiogenic Therapy and Phototherapy\nZheng Weiab ‡, Pingping Liangc ‡, Junqi Xieab, Chuanhui Songab, Chuanchao Tangab, Yufeng Wangab, Xiteng Yinab, Yu Cai* ac, Wei Han* ab, Xiaochen Dong* c\nHerein, nano-integrated strategy is used to unite anti-angiogenic agent, sorafenib, and photosensitizer chlorin e6 to form carrier-free multifunctional nanoparticles (SC NPs) for synergetic anti-angiogenic therapy and phototherapy. The SC NPs (diameter ~152 nm) present excellent water dispersity and passive targeting ability to tumor sites in vivo based on enhanced permeability and retention (EPR) effect, which can be monitored by fluorescence imaging. Besides, SC NPs possess effective reactive oxygen species (ROS) generation and photothermal conversion abilities for both photodynamic therapy (PDT) and photothermal therapy (PTT). At a rather low dosage (200 μg/kg) and illumination with laser (660 nm, 500 mW/cm2), SC NPs can attack tumor tissues by killing the internal tumor cells via mild phototherapy, simultaneously cut off the external nutrient and oxygen supplements of tumor cells via anti-angiogenesis. Besides, oxygen consumption in the PDT process may collaborate with the anti-angiogenic therapy to further cause the cell apoptosis by tumor starvation. In addition to the high efficient therapeutic effect in vivo, SC NPs possess amicable biosafety and biocompatibility, making them promising for fluorescence imaging guided synergetic anti-angiogenic therapy and phototherapy in clinic."
    }, {
      "heading" : "Introduction",
      "text" : "Tumor blood vessels are oxygen and nutrients channels of cancer cells, and one of the main cancer transfer routines in the meantime.1-3 As early in 1994, the Cancer Society of America has recognized that the best way of cancer therapy is to cut off the lifeblood of tumor for the inhibition of tumor growth and stopping their transfer,4-6 as any other ways (surgery, radiation, chemotherapy, and so on) that directly kill cancer cells only temporarily alleviate the disease but hard to avoid the recurrence.7, 8 Anti-angiogenic therapy as a relatively new cancer treatment method aims to suppress the expression of new blood vascular endothelial growth factor (VEGF) with the tumor angiogenesis inhibitors, and induce the natural apoptosis of vascular endothelial cells for destroying tumor angiogenesis net.9-12 Through cutting off the blood supply, the rapid growth of tumor can be effectively inhibited on accounting of the blocked nutrients and oxygen. Therefore, the US food and drug administration (FDA) has recommended tumor angiogenesis inhibitors to be used as an effective\nsupplement along with surgery, radiation and chemotherapy to prevent the tumor spread and metastasis.13, 14 This strategy has significantly increased the five year survival rate of cancer patients in America. However, most angiogenesis inhibitors, such as sorafenib,15 bevacizumab,16 pazopanib17 are small organic molecules with the inherent hydrophobicity and no tumor targeting ability. Consequently, ideal anti-angiogenic protocols and well-designed agents with water dispersity, targeting ability and clinical prospects are extremely sought. In the past decades, phototherapy,18-22 such as photodynamic therapy (PDT)23, 24 and photothermal therapy (PTT),25-27 has attracted extensive research interests for anti-tumors due to the advantages of minimal harm to normal tissues, noninvasiveness, and efficient therapeutic ability.28-30 In PDT, photosensitizers (PSs) under light illumination can generate reactive oxygen species (ROS) including singlet oxygen (1O2) with internal oxygen to casue the tumor cells death, which also indicates PSs may be effective deoxygenating agents to starve the tumor cells for apoptosis.31, 32 Differently, PTT transforms light to heat with the existence of photothermal agents in tumor to induce cellular hyperthermia based necrosis or apoptosis.33, 34 Nevertheless, PTT usually requires very high laser power (> 1 W/cm2) that might cause the surrounding normal tissue damage, while PDT efficacy is plagued by the lesser oxygen level in the tumor sites. Consequently, to devise synergistic tumor treatment to overcome the respective shortcomings and enhance the therapeutic efficiency is highly desirable.\nPage 1 of 7 Chemical Science\nC he\nm ic\nal S\nci en\nce A\ncc ep\nte d\nM an\nus cr\nip t\nO pe\nn A\ncc es\ns A\nrt ic\nle . P\nub lis\nhe d\non 0\n9 Ja\nnu ar\ny 20\n19 . D\now nl\noa de\nd on\n1 /2\n1/ 20\n19 1\n1: 50\n:1 3\nA M . T hi s ar tic le is li ce ns ed u nd er a C re at iv e C om m on s A ttr ib ut io n 3. 0 U np or te d L\nic en\nce .\nView Article Online DOI: 10.1039/C8SC04123G"
    }, {
      "heading" : "ARTICLE Journal Name",
      "text" : "2 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx\nPlease do not adjust margins\nPlease do not adjust margins\nNanoparticles (NPs) hold great promise to selectively deliver therapeutic agents to tumors via the enhanced permeability and retention (EPR) effect, which is also well known as passive targeting.3, 35, 36 Compared to small molecules, nano-agents have the ability to improve the therapeutic efficiency with a much lower dosage, which can decrease the side effects to the normal organs.37, 38 Especially, organic dye based nanoparticles show redshift absorption and emission in the near infrared (NIR) window, which is beneficial to improve the deep penetration of bio-tissues for phototherapy.39, 40 Moreover, the aggregated organic NPs may increase photothermal conversion under the NIR irradiation for more efficient PTT.4144 For instance, Hu et al. combined multifunctional polypyrrole (PPy) camptothecin (CPT) and thermos-cleavable doxorubicin (DOX) prodrug to form CPT@DOX/PPy NPs using a nanointegrated strategy, which were effectively applied for cancer photoacoustic imaging-guided photothermal-chemotherapy.45 Cook et al. designed metallacycles covalent binding boron dipyrromethene (BODIPY) moieties to form self-assembled BODIPY-platinum supramolecular triangles for PDT and chemotherapy.46 However, these synergistic therapeutic nanoagents only focused on the tumor, ignoring the fact that tumor cells still absorb nutrition from the surroundings with the intact blood vessel. Herein, we integrated the anti-angiogenic therapy and phototherapy (PDT and PTT) into one therapeutic strategy by assembling sorafenib (anti-angiogenic agent) and photosensitizer chlorin e6 (Ce6)47, 48 into multifunctional nanoparticles (SC NPs) with a reprecipitation method. The resulted SC NPs present good water dispersity and tumor passive targeting ability based on EPR effect. These SC NPs can attack from within and without of tumors by cutting off the external nutrient and oxygen supplements of tumor cells, and simultaneously kill the internal tumor cells via PDT/PTT. Especially, with the oxygen consumption of the PDT process, tumor cells may further get starved to apoptosis, which collaborates with forces from the outside anti-angiogenic therapy. Because of the synergistic effects from antiangiogenic therapy and phototherapy, the SC NPs can effectively cut off the tumor blood vessels and kill cancer cells\nsimultaneously at a rather low dosage (200 μg/kg) in vivo (Scheme 1)."
    }, {
      "heading" : "Results and Discussion",
      "text" : ""
    }, {
      "heading" : "Synthesis and Characterization",
      "text" : "By reprecipitation, the hydrophobe sorafenib and Ce6 were formed into water soluble SC NPs, which presented a dimension below 200 nm with the spherical morphology, as observed by transmission electron microscopy (TEM, Figure 1a). The dynamic light scattering (DLS) result showed the mean size of SC NPs was ~152 nm (Figure 1b), which makes suitable tumor passive targeting ability with EPR effect.49 The phosphate buffer solution (PBS) of SC NPs with the turquoise color presented clear and transparent even after standing for 7 days in normal condition, meaning its good stability. Besides, SC NPs present excellent stabiliy in plasma, indicating the significative biological stability (Figure S1). The Zeta potential value of SC NPs in water was measured of ~31.99 mv, which\nScheme 1. Schematic illustration of SC NPs formation and their application for synergetic tumor anti-angiogenic therapy and phototherapy.\nFigure 1. (a) TEM image of SC NPs. (b) DLS examination for size distribution of SC NPs in PBS (Insert: photographs of SC NPs standing for 1 day and 7 days, 40 μg/mL). (c) UV-vis absorption spectrum of SC NPs in PBS (pH = 7.4). (d) Fluorescence emission spectra of SC NPs in PBS (pH = 7.4).\nPage 2 of 7Chemical Science\nC he\nm ic\nal S\nci en\nce A\ncc ep\nte d\nM an\nus cr\nip t\nO pe\nn A\ncc es\ns A\nrt ic\nle . P\nub lis\nhe d\non 0\n9 Ja\nnu ar\ny 20\n19 . D\now nl\noa de\nd on\n1 /2\n1/ 20\n19 1\n1: 50\n:1 3\nA M . T hi s ar tic le is li ce ns ed u nd er a C re at iv e C om m on s A ttr ib ut io n 3. 0 U np or te d L\nic en\nce .\nView Article Online DOI: 10.1039/C8SC04123G"
    }, {
      "heading" : "Journal Name ARTICLE",
      "text" : "This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 3\nPlease do not adjust margins\nPlease do not adjust margins\nfurther demonstrated their excellent stability. Due to the existence of Ce6, SC NPs demonstrated excellent NIR absorption in PBS with the peak at 654 nm (Figure 1c), which is suitable for phototherapy in vivo. Moreover, as shown in Figure 1d, obvious fluorescence peak of SC NPs in PBS emitting with the peak at 670 nm suggests their potential application for fluorescence imaging. In Vitro Multifunctionality To evaluate the multifunctionality of SC NPs, the photothermal conversion efficiency, the fluorescence imaging property, and the reactive oxygen species (ROS) generation of SC NPs were respectively meaured in PBS. As shown in Figure 2a, SC NPs solution presented an apparent fluorescence signal, which was enhanced with the increased concentration, and the fluorescence imaging intensity presented the brightest signal at 40 μg/mL. Ce6 has been proved to be an excellent photosensitizer with efficient ROS generation, thereby the ROS generation ability of SC NPs was further measured by using 9, 10-anthracenediyl-bis (methylene) dimalonic acid (ABDA, absorption peak at 378 nm)50 as a probe. As shown in Figure 2b, under the laser illuminaiton (660 nm, 500 mW/cm2), the absorption density of ABDA at 378 nm rapidly decreased over time, indicating SC NPs possess high ability to generate ROS in PBS for PDT. Figure 2c shows the relationship between the temperature difference (ΔT) and SC NPs concentrations under laser irradiation, showing the concentration dependent of the photothermal conversion. With the concentration of SC NPs increased to 40 μg/mL, the temperature of the solution increadsed 24 °C in 60 s. Then, the ΔT gradually rose to over 30 °C. In the meantime, with the laser power increasing, the ΔT of SC NPs solution also heightened (Figure 2d). The photothermal conversion efficiency of SC NPs is calculated of ~48.0%, which is much higher than numerous reported organic photothermal agents.41, 51-53 These results indicate the multifunctionality of SC NPs as a new type of potential theranostic nano-agent for cancer fluorescence imaging, PDT and PTT. Tumor Cellular Uptake and Cytotoxicity SC NPs with an fluorescence emission peak at ~670 nm, indicating the cellular uptake may be visualized. By the green color revealation of confocal fluorescence imaging, SC NPs (10 μg/mL, 200 μL) can be readily taken up into HSC3 cells with incubation for 24 h (Figure 3a, up panel). Moreover, by using the confocal microscope method for 3D reconstruction of the specimen surface, SC NPs were confirmed to be located in the HSC3 cells via observing from cell profile (Figure 3a, down panel) and a video of 3D view of the cells was recorded (seeing in the supporting information). The cytotoxicity was assessed by using Cell Counting Kit-8 (CCK-8) assays54 in vitro in HSC3 cells incubated with SC NPs in different concentrations with or without illumination (660 nm, 500 mW/cm2). It was obviously found the cell viability decreased with laser illumination, of which the half-maximal inhibitory concentration (IC50) value was calculated of 0.8808 μg/mL, indicating high efficient PDT/PTT and chemotherapy synergetic effect of SC NPs (Figure 3b). Different form the laser illumination group, the other group (no special irradiation) exhibited much lower cell toxicity (IC50: ~22.45 μg/mL) because of the slight chemotherapeutic effect of sorafenib, demonstrating the desirable biocompatibility of SC NPs. Most anticancer drugs activate cell apoptosis to kill tumor cells, thereby the FITC-Annexin V/propidium iodide (PI) method55 was employed for th apoptosis analysis. HSC3 cells were cultured with SC NPs with or without the condition of laser illumination (660 nm, 500\nmW/cm2) at the concentration of 10 μg/mL, and a group of blank cells were taken as control. As shown in the flow cytometry analysis, the ratio of apoptotic cells was 16.18% and\nFigure 2. (a) The relationship between the fluorescence imaging intensity and the concentration of SC NPs in PBS (pH 7.4). (b) Absorption spectra at 379 nm of the mixture of SC NPs (40 μg/mL) and ABDA (10-4 mol/L) under illumination in PBS (pH 7.4) over time. (c) Photothermal conversion of SC NPs at different concentrations in PBS (pH 7.4) under laser irradiation (660 nm, 500 mW/cm2). (d) Photothermal conversion of SC NPs (40 μg/mL) in PBS (pH 7.4) with different power densities.\nFigure 3. (a) Fluorescence imaging of SC NPs in HSC3 cells: left panel, DAPI channel; middle panel, fluorescence images; right panel, merged images; up panel, planform; down panel, side view. (b) CCK-8 assays of HSC3 cells incubated with SC NPs in different condition. (c) Apoptotic rates of blank HSC3 cells. (d) Apoptotic rates of HSC3 cells treated with SC NPs only. (e) Apoptotic rates of HSC3 cells treated with SC NPs and laser irradiation.\nPage 3 of 7 Chemical Science\nC he\nm ic\nal S\nci en\nce A\ncc ep\nte d\nM an\nus cr\nip t\nO pe\nn A\ncc es\ns A\nrt ic\nle . P\nub lis\nhe d\non 0\n9 Ja\nnu ar\ny 20\n19 . D\now nl\noa de\nd on\n1 /2\n1/ 20\n19 1\n1: 50\n:1 3\nA M . T hi s ar tic le is li ce ns ed u nd er a C re at iv e C om m on s A ttr ib ut io n 3. 0 U np or te d L\nic en\nce .\nView Article Online DOI: 10.1039/C8SC04123G"
    }, {
      "heading" : "ARTICLE Journal Name",
      "text" : "4 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx\nPlease do not adjust margins\nPlease do not adjust margins\n93.36% in no irradiation and irradiation groups, respectively (Figure 3c-e). In comparison with the no irradiation group, laser irradiation promotes a much higher apoptotic cell rate with the same dosage. These results further demonstrate SC NPs have great therapeutic effect on tumor cells induced by both phototherapy and chemotherapy. ROS Generation in Vitro Cytotoxic ROS has been proved to cause cell damage in the progress of PDT. The ROS generation ability of SC NPs was further examined by using 2′,7′-dichlorofluorescein diacetate (DCFH-DA) as a fluorogenic probe in tumor cells. DCFH-DA has no fluorescence itself, and it produces 2′,7′-dichlorofluorescein (DCF) with fluorescence when reacting with ROS.56 As revealed in Figure 4a, bright fluorescence imaging was viewed in the culture dish of SC NPs with DCFH-DA in HSC3 cells after laser irradiation (660 nm, 500 mW/cm2), which was cuasued by the generation of fluorescent DCF in HSC3 cells. In contrast, little fluorescence emitted when these cells were kept out of light. The results of flow cytometry show that the group of SC NPs with DCFH-DA in HSC3 cells under laser irradiation was more than an order of magnitude higher than those cells cultured with SC NPs without laser irradiation (Figure 4b). By using a microplate reader, the DCF generation intensity of SC NPs with DCFH-DA in HSC3 cells under laser irradiation was further confirmed (Figure 4c). Anti-angiogenesis Assay in Vitro To determine the anti-angiogenic effect of SC NPs in tumor endothelial cells, the uptake, cytotoxicity, cell cycle, cell apoptosis, tube formation anti-angiogenesis assay were assessed. By using the flow cytometric analyses, as shown in Figure 5a, SC NPs (10 μg/mL, 200 μL) can be gradually taken up into human umbilical vein endothelial cells (HUVECs) after the incubation for 12 h,57 and slightly discharged at 24 h, which indicates SC NPs can be efficiently endocytosed into HUVECs. Sorafinib has been proved to have dual antitumor effects, which can not only be mediated by blocking the RAF/MEK/ERK signaling pathways and directly inhibit the tumor cell proliferation, but also inhibit the expression of VEGF, plateletderived growth factor (PDGF) receptor, and the formation of tumor angiogenesis to indirectly inhibit the growth of tumor cells.58 As shown in Figure 5b, the cytotoxicity was assessed in vitro by using CCK-8 assays in HUVECs and HSC3 cells incubated with SC NPs of different concentrations. It can be found that the cell viability of HUVECs obviously decreased and the IC50 is ~0.2634 μg/mL, indicating the high inhibitory effect of SC NPs on HUVECs. In comparison, HSC3 cells exhibited much lower cell toxicity (IC50: ~22.45 μg/mL). Figure 5c shows that the HUVECs treated with SC NPs were mostly arrested at the cycle G0/G1, indicating the cells lost their ability to dissociate, and turn to the process of differentiation, aging, and cell death. FITC-Annexin V/PI method was futher employed for the death analysis of HUVECs incubated with SC NPs. As shown in Figure 5d and 5e, in comparison with the blank control, HUVECs treated with SC NPs were promoted to reach a much higher apoptotic rate (79.0%), and the flow cytometry analysis showed most of HUVECs were apoptotic induced by the SC NPs. To further assess the anti-angiogenic effect of SC NPs, HUVEC cell tube formation and antiangiogenesis assay was performed. As shown in 5f, after the cell tube formation completed, SC NPs were added to these cell tubes, which made the fine structure of the blood vessels gradually decomposed. At 10 h, almost no vessel structure was observed, indicating SC NPs can effectively destroy the cell tubes via anti-angiogenesis. By contrast, the blood vessels in the blank control group presented the tendency to grow naturally. In Vivo Imaging Figure 6a shows the fluorescence images of mice with intravenous injection of SC NPs. After the post injection of 1 h, the fluorescence signal can be observed in the tumor sites and\nlast for about 6 hours, indicating the excellent fluorescence imaging in vivo and EPR effect based tumor targeting ability. The retention time of SC NPs in the tumor sites also provides bounteous time for the subsequent treatment. After 8 h, the\nFigure 4. (a) Fluorescence imaging of SC NPs and DCFH-DA mixture in HSC3 cells with or without laser irradiation (660 nm, 500 mW/cm2). Scale bar: 50 μm. (b) Flow cytometric analyses. (c) DCF intensity in different groups. ****, P < 0.0001.\nFigure 5. (a) Flow cytometric analyses of SC NPs uptake in HUVECs. (b) CCK-8 assays of HSC3 cells and HUVECs incubated with SC NPs. (c) HUVEC cell cycle incubated with SC NPs. (d) Apoptosis of blank control HUVECs. (e) Apoptosis of HUVECs incubated with SC NPs. (f) In vitro endothelial cell tube formation and anti-angiogenesis assay. Scale bar: 100 μm.\nPage 4 of 7Chemical Science\nC he\nm ic\nal S\nci en\nce A\ncc ep\nte d\nM an\nus cr\nip t\nO pe\nn A\ncc es\ns A\nrt ic\nle . P\nub lis\nhe d\non 0\n9 Ja\nnu ar\ny 20\n19 . D\now nl\noa de\nd on\n1 /2\n1/ 20\n19 1\n1: 50\n:1 3\nA M . T hi s ar tic le is li ce ns ed u nd er a C re at iv e C om m on s A ttr ib ut io n 3. 0 U np or te d L\nic en\nce .\nView Article Online DOI: 10.1039/C8SC04123G"
    }, {
      "heading" : "Journal Name ARTICLE",
      "text" : "This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 5\nPlease do not adjust margins\nPlease do not adjust margins\nfluorescence was decreased in tumors, meaning the NPs were gradually eliminated from the tumors. After 10 h, these mice were sacrificed for ex vivo fluorescence imaging study. Weak fluorescence signal can be observed in the tumors as SC NPs were wiped out from the tumor sites. Strong fluorescence was observed in the detoxification organ, liver, which indicates most of the SC NPs were metabolized by the liver. Based on the fluorescence imaging consequence, in vivo thermal imaging of SC NPs was further investigated with laser\nirradiation (660 nm, 500 mW/cm2) after 1 h post injection. As revealed in Figure 6b, the tumor temperature rapidly increased and reached ~55 °C with the illumination for 6 min. Differently, the tumor temperature of the control group showed nearly no change, which confirms the good photothermal conversion of SC NPs and their tumor passive targeting ability. In Vivo Imaging-Guided Therapy To examine the in vivo toxicity and the therapeutic effect of SC NPs, HSC3 tumor-bearing mice were falled into 3 groups randomly for receiving different treatments. Figure 7a shows that all groups similarly increased the body weight, indicating the low toxicity and good biocompatibility of the NPs. As shown in Figure 7b and c, the volumes of tumors in the control group increased quickly, and the group injected with SC NPs without any special illumination presented slight tumor suppression, which may be casued by the anti-angiogenic effect of sorafenib in the NPs. Remarkably, SC NPs injection followed by laser illumination (660 nm, 500 mW/cm2) can greatly inhibit tumor growth. In contrast, free sorafenib (200 μg/kg) and Ce6 (200 μg/kg) were also injected to tumorbearing mice with or without laser irradiation, both of the groups showed little therapeutic efficacy (Figure S2), indicating the nanomedicine are much more effective than the traditional dosage form. All the mice were sacrificed in the end of 12 days treatments, and the haematoxylin and eosin (H&E) stained tumor tissue analyses59 were then conducted. Tumors in the control group presented the pretty low differentiation of tumor cells, and the proportion of nucleolus was large and the morphology of cells was the same. Differently, necrotic cells can be found in the groups treated with either SC NPs or SC NPs + 660 nm laser irradiation (Figure 7d). To further visually identify the proliferation of tumors, the marker of Ki-76 was stained with tumors.60 As shown in Figure 7e, the tumor cells in the control group are dark brown, stained strongly positive, and the number of positive cells was calculated to be over 80%, indicating that cell proliferation was much stronger. On the contrary, tumors treated with SC NPs and laser irradiation show Ki-67 staining negative, indicating that proliferation of tumor cells was significantly weak. Besides, the positive cells number and Ki-67 intensity were only observed in SC NPs treated groups. These examinations of tumor immunohistochemical study confirm that the SC NPs + 660 nm laser irradiation group exhibit the highest inhibition efficacy and SC NPs hold the ability to inhibit tumor growth. The biosafety of SC NPs after treatment were also evaluated. As presented in Figure 8, similar to the blank control group, H&E staining results of the major organs were found no obvious histological variations both in SC NPs only and SC NPs + laser irradiation groups, which indicates the great biosafety and biocompatibility of SC NPs."
    }, {
      "heading" : "Conclusions",
      "text" : "In summary, the multifunctional carrier-free SC NPs have been successfully prepared by the assembly of sorafenib and Ce6 via reprecipitation method, which can attack from within and\nFigure 7. (a) Body weight change of the mice in different groups. (b) Changes of the tumor volume in different groups. *, P < 0.05; ***, P < 0.001; ****, P < 0.0001 (significant differences compared to the laser only group). (c) Tumors excised from the mice in different groups after the treatment for 12 days. (d) H&E and (e) Ki-67 staining of tumor tissues treated with laser only, SC NPs only and SC NPs + laser groups.\nPage 5 of 7 Chemical Science\nC he\nm ic\nal S\nci en\nce A\ncc ep\nte d\nM an\nus cr\nip t\nO pe\nn A\ncc es\ns A\nrt ic\nle . P\nub lis\nhe d\non 0\n9 Ja\nnu ar\ny 20\n19 . D\now nl\noa de\nd on\n1 /2\n1/ 20\n19 1\n1: 50\n:1 3\nA M . T hi s ar tic le is li ce ns ed u nd er a C re at iv e C om m on s A ttr ib ut io n 3. 0 U np or te d L\nic en\nce .\nView Article Online DOI: 10.1039/C8SC04123G"
    }, {
      "heading" : "ARTICLE Journal Name",
      "text" : "6 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx\nPlease do not adjust margins\nPlease do not adjust margins\nwithout of the tumor by both cutting off the external nutrient and oxygen supplements of tumor cells and kill the internal tumor cells via PDT/PTT. SC NPs present excellent water dispersity and passive targeting ability to tumor tissues based on the EPR effect, and can be monitored by fluorescence imaging in vivo. With the synergistic effect from antiangiogenic therapy and phototherapy, SC NPs effectively cut off the tumor blood vessels and kill cancer cells simultaneously with a rather low dose (200 μg/kg) in vivo. Besides, the examinations of tumor immunohistochemical study confirm that SC NPs exhibit high inhibition efficacy to tumor and have great biosafety and biocompatibility. We show that SC NPs achieve much lower effective dose and moderate laser irradiation for synergistic anti-angiogenic therapy and phototherapy and have potential application in clinic."
    }, {
      "heading" : "Conflicts of interest",
      "text" : "The authors declare no conflict of interest."
    }, {
      "heading" : "Acknowledgements",
      "text" : "The work was supported by the NNSF of China (61525402, 61775095), Jiangsu Provincial Key Research and Development Plan (BE2017741), the Fundamental Research Funds for the Central Universities (021414380350), Jiangsu Provincial Natural Science Foundation (BK20180136, BK20160051), Nanjing Foundation for Development of Science and Technology (2017sc512031, 201605042)."
    }, {
      "heading" : "Ethical Statement",
      "text" : "All animal procedures were performed in accordance with the\nGuidelines for Care and Use of Laboratory Animals of the\nMedical School of Nanjing University and Experiments were\napproved by the Animal Ethics Committee of Nanjing\nStomatological Hospital."
    }, {
      "heading" : "Notes and references",
      "text" : "1. A. Karimi, R. Shahrooz, R. Hobbenaghi, R. Mohammadi and E. Mortaz, Cell J., 2018, 19, 578-584. 2. M. Valko, D. Leibfritz, J. Moncol, M. T. D. Cronin, M.\nMazur and J. Telser, Int. J. Biochem. Cell Biol., 2007, 39, 44-84.\n3. S. Wilhelm, A. J. Tavares, Q. Dai, S. Ohta, J. Audet, H. F. Dvorak and W. C. W. Chan, Nat. Rev. Mater., 2016, 1, 16014. 4. J. Folkman, Nat. Med., 1995, 1, 27-31. 5. M. Gao, C. Liang, X. Song, Q. Chen, Q. Jin, C. Wang and Z. Liu, Adv. Mater., 2017, 29, 1701429. 6. C. Zhang, D. Ni, Y. Liu, H. Yao, W. Bu and J. Shi, Nat. Nanotechnol., 2017, 12, 378-386. 7. G. Chen, R. Jaskula-Sztul, C. R. Esquibel, I. Lou, Q.\nZheng, A. Dammalapati, A. Harrison, K. W. Eliceiri, W. Tang, H. Chen and S. Gong, Adv. Funct. Mater., 2017, 27, 1604671.\n8. P. Sharma and J. P. Allison, Science, 2015, 348, 56-61. 9. J. Zhang, J. Li, Z. Shi, Y. Yang, X. Xie, S. M. Lee, Y.\nWang, K. W. Leong and M. Chen, Acta Biomater., 2017, 58, 349-364.\n10. P. Carmeliet and R. K. Jain, Nature, 2000, 407, 249- 257. 11. P. Carmeliet and R. K. Jain, Nature, 2011, 473, 298- 307. 12. M. de Palma, D. Biziato and T. V. Petrova, Nat. Rev. Cancer, 2017, 17, 457-474. 13. Y. Zhang, Y. Chen, D. Zhang, L. Wang, T. Lu and Y. Jiao, J. Med. Chem., 2018, 61, 140-157. 14. R. Roskoski, Jr., Pharmacol. Res., 2017, 120, 116-132. 15. R. Zhao, T. Li, G. Zheng, K. Jiang, L. Fan and J. Shao, Biomaterials, 2017, 143, 1-16. 16. R. Zhu, Z. Wang, P. Liang, X. He, X. Zhuang, R. Huang,\nM. Wang, Q. Wang, Y. Qian and S. Wang, Acta Biomater., 2017, 63, 163-180.\n17. S. Torok, M. Rezeli, O. Kelemen, A. Vegvari, K. Watanabe, Y. Sugihara, A. Tisza, T. Marton, I. Kovacs, J. Tovari, V. Laszlo, T. H. Helbich, B. Hegedus, T. Klikovits, M. A. Hoda, W. Klepetko, S. Paku, G. MarkoVarga and B. Dome, Theranostics, 2017, 7, 400-412. 18. H. Zhao, W. Hu, H. Ma, R. Jiang, Y. Tang, Y. Ji, X. Lu, B. Hou, W. Deng, W. Huang and Q. Fan, Adv. Funct. Mater., 2017, 27, 1702592. 19. L. Cheng, C. Wang, L. Feng, K. Yang and Z. Liu, Chem. Rev., 2014, 114, 10869-10939. 20. Y. Lyu, Y. Fang, Q. Miao, X. Zhen, D. Ding and K. Pu, ACS Nano, 2016, 10, 4472-4481. 21. H. Zhu, Y. Fang, Q. Miao, X. Qi, D. Ding, P. Chen and K. Pu, ACS Nano, 2017, 11, 8998-9009. 22. Q. Miao, C. Xie, X. Zhen, Y. Lyu, H. Duan, X. Liu, J. V. Jokerst and K. Pu, Nat. Biotechnol., 2017, 35, 1102- 1110. 23. J. Liu, H. Liang, M. Li, Z. Luo, J. Zhang, X. Guo and K. Cai, Biomaterials, 2018, 157, 107-124. 24. J.-n. Liu, W. Bu and J. Shi, Chem. Rev., 2017, 117, 6160-6224.\nPage 6 of 7Chemical Science\nC he\nm ic\nal S\nci en\nce A\ncc ep\nte d\nM an\nus cr\nip t\nO pe\nn A\ncc es\ns A\nrt ic\nle . P\nub lis\nhe d\non 0\n9 Ja\nnu ar\ny 20\n19 . D\now nl\noa de\nd on\n1 /2\n1/ 20\n19 1\n1: 50\n:1 3\nA M . T hi s ar tic le is li ce ns ed u nd er a C re at iv e C om m on s A ttr ib ut io n 3. 0 U np or te d L\nic en\nce .\nView Article Online DOI: 10.1039/C8SC04123G"
    }, {
      "heading" : "Journal Name ARTICLE",
      "text" : "This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 7\nPlease do not adjust margins\nPlease do not adjust margins\n25. Z. Tang, H. Zhang, Y. Liu, D. Ni, H. Zhang, J. Zhang, Z. Yao, M. He, J. Shi and W. Bu, Adv. Mater., 2017, 29, 1701683. 26. Y. Zhang, D. Yang, H. Chen, W. Q. Lim, F. S. Z. Phua, G. An, P. Yang and Y. Zhao, Biomaterials, 2018, 163, 14- 24. 27. H. Lin, X. Wang, L. Yu, Y. Chen and J. Shi, Nano Lett., 2017, 17, 384-391. 28. J. Li, J. Rao and K. Pu, Biomaterials, 2018, 155, 217- 235. 29. Y. Jiang and K. Pu, Acc. Chem. Res., 2018, 51, 1840- 1849. 30. J. Li and K. Pu, Chem. Soc. Rev., 2018, DOI: 10.1039/c8cs00001h. 31. Y. Cai, Q. Tang, X. Wu, W. Si, Q. Zhang, W. Huang and X. Dong, ACS Appl. Mater. Interfaces, 2016, 8, 10737- 10742. 32. Q. Jia, J. Ge, W. Liu, X. Zheng, S. Chen, Y. Wen, H. Zhang and P. Wang, Adv. Mater., 2018, 30, 1706090. 33. X. Huang, W. Zhang, G. Guan, G. Song, R. Zou and J. Hu, Acc. Chem. Res., 2017, 50, 2529-2538. 34. X. Yao, X. Niu, K. Ma, P. Huang, J. Grothe, S. Kaskel and Y. Zhu, Small, 2017, 13, 1602225. 35. S. Wang, L. Shang, L. Li, Y. Yu, C. Chi, K. Wang, J. Zhang, R. Shi, H. Shen, G. I. N. Waterhouse, S. Liu, J. Tian, T. Zhang and H. Liu, Adv. Mater., 2016, 28, 8379-8387. 36. T. Sun, Y. S. Zhang, B. Pang, D. C. Hyun, M. Yang and Y. Xia, Angew. Chem., Int. Ed., 2014, 53, 12320- 12364. 37. J. Qi, C. Sun, A. Zebibula, H. Zhang, R. T. K. Kwok, X. Zhao, W. Xi, J. W. Y. Lam, J. Qian and B. Z. Tang, Adv. Mater., 2018, 30, 1706856. 38. W. Qin, D. Ding, J. Liu, W. Z. Yuan, Y. Hu, B. Liu and B. Z. Tang, Adv. Funct. Mater., 2012, 22, 771-779. 39. T. Sun, J.-H. Dou, S. Liu, X. Wang, X. Zheng, Y. Wang, J. Pei and Z. Xie, ACS Appl. Mater. Interfaces, 2018, 10, 7919-7926. 40. H. Zhu, J. Li, X. Qi, P. Chen and K. Pu, Nano Lett., 2018, 18, 586-594. 41. Y. Cai, W. Si, Q. Tang, P. Liang, C. Zhang, P. Chen, Q. Zhang, W. Huang and X. Dong, Nano Res., 2017, 10, 794-801. 42. K. Ding, Y. Zhang, W. Si, X. Zhong, Y. Cai, J. Zou, J. Shao, Z. Yang and X. Dong, ACS Appl. Mater. Interfaces, 2018, 10, 238-247. 43. Y. Cai, P. Liang, W. Si, B. Zhao, J. Shao, W. Huang, Y. Zhang, Q. Zhang and X. Dong, Org. Chem. Front., 2018, 5, 98-105. 44. Y. Jiang, D. Cui, Y. Fang, X. Zhen, P. K. Upputuri, M. Pramanik, D. Ding and K. Pu, Biomaterials, 2017, 145, 168-177. 45. J. Yang, S. Zhai, H. Qin, H. Yan, D. Xing and X. Hu, Biomaterials, 2018, 176, 1-12. 46. J. Zhou, Y. Zhang, G. Yu, M. R. Crawley, C. R. P. Fulong, A. E. Friedman, S. Sengupta, J. Sun, Q. Li, F. Huang and T. R. Cook, J. Am. Chem. Soc., 2018, 140, 7730- 7736. 47. F. Xia, W. Hou, Y. Liu, W. Wang, Y. Han, M. Yang, X. Zhi, C. Li, D. Qi, T. Li, J. Martinez de la Fuente, C. Zhang, J. Song and D. Cui, Biomaterials, 2018, 170, 1- 11. 48. T. Hu, J. He, S. Zhang, X. Mei, W. Zhang, R. Liang, M. Wei, D. G. Evans and X. Duan, Chem. Commun., 2018, 54, 5760-5763. 49. H. S. Peng and D. T. Chiu, Chem. Soc. Rev., 2015, 44, 4699-4722. 50. Y. Cai, Q. Tang, X. Wu, W. Si, W. Huang, Q. Zhang and X. Dong, ChemistrySelect, 2016, 1, 3071-3074. 51. Y. Cai, P. Liang, Q. Tang, X. Yang, W. Si, W. Huang, Q. Zhang and X. Dong, ACS Nano, 2017, 11, 1054-1063. 52. H. J. Yoon, H. S. Lee, J. Y. Lim and J. H. Park, ACS Appl. Mater. Interfaces, 2017, 9, 5683-5691. 53. B. Guo, Z. Sheng, D. Hu, A. Li, S. Xu, P. N. Manghnani, C. Liu, L. Guo, H. Zheng and B. Liu, ACS Nano, 2017, 11, 10124-10134. 54. X. Duan, T. Bai, J. Du and J. Kong, J. Mater. Chem. B, 2018, 6, 39-43. 55. X. Zhu, Y. Sun, D. Chen, J. Li, X. Dong, J. Wang, H. Chen, Y. Wang, F. Zhang, J. Dai, R. P. Pirraco, S. Guo, A. P. Marques, R. L. Reis and W. Li, J. Controlled Release, 2017, 254, 107-118. 56. Q. Sun, Q. You, X. Pang, X. Tan, J. Wang, L. Liu, F. Guo, F. Tan and N. Li, Biomaterials, 2017, 122, 188-200. 57. C. Song, Y. Zhang, C. Li, G. Chen, X. Kang and Q. Wang, Adv. Funct. Mater., 2016, 26, 4192-4200. 58. W. M. Eldehna, M. Fares, H. S. Ibrahim, M. H. Aly, S. Zada, M. M. Ali, S. M. Abou-Seri, H. A. Abdel-Aziz and D. A. A. El Ella, Eur. J. Med. Chem., 2015, 100, 89-97. 59. J. Xue, Z. Zhao, L. Zhang, L. Xue, S. Shen, Y. Wen, Z. Wei, L. Wang, L. Kong, H. Sun, Q. Ping, R. Mo and C. Zhang, Nat. Nanotechnol., 2017, 12, 692-700. 60. O. Fluge, K. Gravdal, E. Carlsen, B. Vonen, K. Kjellevold, S. Refsum, R. Lilleng, T. J. Eide, T. B. Halvorsen, K. M. Tveit, A. P. Otte, L. A. Akslen, O. Dahl and G. Norwegian Gastrointestinal Canc, Br. J. Cancer, 2009, 101, 1282-1289.\nPage 7 of 7 Chemical Science\nC he\nm ic\nal S\nci en\nce A\ncc ep\nte d\nM an\nus cr\nip t\nO pe\nn A\ncc es\ns A\nrt ic\nle . P\nub lis\nhe d\non 0\n9 Ja\nnu ar\ny 20\n19 . D\now nl\noa de\nd on\n1 /2\n1/ 20\n19 1\n1: 50\n:1 3\nA M . T hi s ar tic le is li ce ns ed u nd er a C re at iv e C om m on s A ttr ib ut io n 3. 0 U np or te d L\nic en\nce .\nView Article Online DOI: 10.1039/C8SC04123G"
    } ],
    "references" : [ ],
    "referenceMentions" : [ ],
    "year" : 2019,
    "abstractText" : "Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal’s standard Terms & Conditions and the ethical guidelines, outlined in our author and reviewer resource centre, still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains. Accepted Manuscript",
    "creator" : "Aspose Ltd."
  }
}